# PLUVICTO

- **Website:** <https://pluvicto.com>
- **Primary alias:** `pluvicto.com`

## Description

PLUVICTO, by Novartis Pharmaceuticals Corporation, is a targeted treatment for men with PSMA+ metastatic castration-resistant prostate cancer (mCRPC). PLUVICTO® (lutetium Lu 177 vipivotide tetraxetan) is a radiopharmaceutical designed to address this advanced cancer condition. Patients can find more information on prescribing and safety on their website, which is tailored for US residents only.

For those seeking treatment, PLUVICTO offers a patient video featuring an individual sharing their treatment journey, providing valuable insights. Additionally, there is a video showcasing the production process of PLUVICTO, highlighting how this treatment is created and delivered within a short timeframe of 5 days.

Understanding PLUVICTO is crucial, as it involves exposure to radioactivity. Patients can learn more about its approved use and important safety information on the website. For those in need of targeted treatment for PSMA+ mCRPC, PLUVICTO may be a valuable option to explore.

## Industries

- ⛑ Health
- ⛑ Biotechnology and Pharmaceuticals _(under Health)_

## Logos & icons

- logo _(primary)_ — PNG — [download](https://cdn.brandfetch.io/idL7Chal8W/w/468/h/163/theme/dark/logo.png?c=1bxid64Mup7aczewSAYMX&t=1789137463580)

## Colors

| Name | Hex | Theme |
| --- | --- | --- |
| Chathams Blue | #1d418b | accent |
| Hawaiian Tan | #a55519 | dark |
| Rajah | #f7c67b | light |

## Fonts

- var(--font_secondary) — asset _(custom)_
- var(--font_primary) — asset _(custom)_

---

_Source: <https://brandfetch.com/pluvicto.com>_
_See [/llms.txt](/llms.txt) for a full list of agent-readable pages, and [/auth.md](/auth.md) for how agents authenticate._